LA
GNMX

Legacy Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Legacy Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,450
Closed – – 360
2019
Q2 		$0 Hold
2,450
– – ﹤0.01% 432
2019
Q1 		$0 Buy
+2,450
New +$544 ﹤0.01% 407
2018
Q4 		– Sell
-2,450
Closed -$3K – 439
2018
Q3 		$3K Hold
2,450
– – ﹤0.01% 435
2018
Q2 		$3K Hold
2,450
– – ﹤0.01% 379
2018
Q1 		$4K Hold
2,450
– – ﹤0.01% 318
2017
Q4 		$2K Hold
2,450
– – ﹤0.01% 333
2017
Q3 		$3K Hold
2,450
– – ﹤0.01% 318
2017
Q2 		$3K Hold
2,450
– – ﹤0.01% 185
2017
Q1 		$4K Hold
2,450
– – 0.01% 179
2016
Q4 		$12K Buy
+2,450
New +$12.9K 0.02% 164

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legacy Advisors's GNMX Position: Q3 2019 in Review

Legacy Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2019, closing a stake of 2,450 shares.

Legacy Advisors first reported a position in GNMX in Q4 2016 and held it in 10 quarters. The position peaked at $12K in Q4 2016. 25 funds tracked by Wall St. Rank hold GNMX as of Q3 2019.

  • Legacy Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q3 2019 after selling out during the quarter.
  • Legacy Advisors sold 2,450 Aevi Genomic Medicine Inc shares in Q3 2019.
  • Legacy Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 10 quarters.
  • Legacy Advisors's Aevi Genomic Medicine Inc position peaked at $12K in Q4 2016.
  • 25 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2019.

Based on Legacy Advisors's 13F filing for Q3 2019, filed 10 Oct 2019.